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SWOSU College of Pharmacy Rural Health Network
RURAL ROCKS
RECALLS
Dexcom Inc. Recalls G4 Platinum and G5 Mobile Continuous Glucose Monitoring System Receivers
Due to Audible Alarm Failure
ohttp://www.fda.gov/MedicalDevices/Safety/ListofRecalls/ucm495448.htm?source=govdelivery&
utm_medium=email&utm_source=govdelivery
04/13/2016 Hospira
50%
Magnesium
Sulfate
Injection,
USP
Particulate Matter Hospira, Inc.
04/11/2016 Super Herbs
Super Herbs
Capsules,
Weight
Loss
Dietary
Supplemen
t
Unapproved new drug-
FDA laboratory
testing found SUPER
HERBS to contain
sibutramine,
desmethylsibutramine
, and/or
phenolphthalein.
Super Herbs
RURAL ROCKS
RECALLS
 50% Magnesium Sulfate Injection, USP
 Super Herbs Capsules, Weight Loss Dietary
Supplement
 Marketed as a dietary supplement
 5% Dextrose Injection USP
 8.4% Sodium Bicarbonate Injection, USP
 Amikacin sulfate injection USP, 1 gram/4mL (250
mg/mL)
 Fluconazole Injection, USP, (in 0.9% Sodium Chloride)
200mg per 100mL
SHORTAGES
 Numerous products
FDA Drug Safety Communication:
 FDA adds warnings about heart failure risk to labels of
type 2 diabetes medicines containing saxagliptin and
alogliptin
HIPAA update
 Ready or Not, It’s Time For Phase 2 HIPAA Audits
INSURANCE
 New Medicare Payment Model Aims To Improve
Primary Care
 Pharmacy Drug Pricing
IMMUNIZATIONS
 CDC Vaccine Price List
HOSPITAL
 Joint Commission Resources
UPDATES
 CARDIOLOGY USPSTF: Update to Aspirin Use Guidelines
 Depression May Compound Diabetes Risk  (from
consultant360)
 New research investigates the association between
depression and metabolic risk factors and the likelihood
of developing type 2 diabetes
 New Prostate Technique May Help Men's Nighttime
Urination
NEWS
 For Consumers: Seven Things Pregnant Women
and Parents Need to Know About Arsenic in Rice
and Rice Cereal
 Scientists Try to Stop Another Deadly Virus
 Doctors Often Overestimate Promise of Newly
Approved Drugs
 Many misinterpret FDA 'breakthrough'
designation, survey finds
 3 Findings on Colds You May Have Missed
 Prediabetes May Damage Nerves More Than
Thought
04/05/2016 ContinuumLabs
Marketed as a
dietary
supplement Contains Ligandrol
INVISIBLU
Internationa
l LLC
03/28/2016
B. Braun
Medical
Inc.
5% Dextrose
Injection
USP
Leakage and visible
particulate matter
(microbial growth)
B. Braun
Medical
Inc.
03/18/2016 Hospira
8.4% Sodium
Bicarbonat
e Injection,
USP
Presence of particulate
matter Hospira Inc.
03/09/2016
Teva
Pharmaceutic
als
Amikacin
sulfate
injection
USP, 1
gram/4mL
(250
mg/mL)
Due to the potential
presence of
particulate matter
identified as glass in
one vial
Teva
Pharmaceut
icals
03/01/2016
Sagent
Pharmaceutic
als, Inc.
Fluconazole
Injection,
USP, (in
0.9%
Sodium
Chloride)
200mg per
100mL
 SHORTAGES
 April 07, 2016
 Theophylline Extended Release Tablets and Capsules (Currently in Shortage)
 April 05, 2016
 Theophylline Extended Release Tablets and Capsules (Currently in Shortage)
 March 17, 2016
 Rivastigmine Tartrate Capsules (Discontinuation)
 March 11, 2016
 Didanosine Delayed-Release Capsules USP (Discontinuation)
 Telithromycin (Ketek) Tablets (Discontinuation)
 March 04, 2016
 Enoxaparin Sodium Injection (Discontinuation)
 Updated
 April 13, 2016
 Piperacillin and Tazobactam (Zosyn) Injection (Currently in Shortage)
 April 11, 2016
 Calcium Gluconate Injection (Currently in Shortage)
 Cefepime Injection (Currently in Shortage)
 Cefotetan Disodium Injection (Currently in Shortage)
 Imipenem and Cilastatin for Injection, USP (Currently in Shortage)
 Lidocaine Hydrochloride (Xylocaine) Injection (Currently in Shortage)
 Methylprednisolone Sodium Succinate for Injection, USP (Currently in Shortage)
 Potassium Chloride Injection (Currently in Shortage)
 Sodium Chloride 23.4% Injection (Currently in Shortage)
 Theophylline Extended Release Tablets and Capsules (Currently in Shortage)
 Tigecycline (Tygacil) Injection (Currently in Shortage)
 Tiopronin (Thiola) (Resolved)
 Tobramycin Injection (Currently in Shortage)
 Vancomycin Hydrochloride for Injection, USP (Currently in Shortage)
 April 07, 2016
 Chloroquine Phosphate Tablets (Resolved)
 Potassium Acetate Injection, USP (Currently in Shortage)
 April 05, 2016
 Dexamethasone Sodium Phosphate Injection (Currently in Shortage)
 Fentanyl Citrate (Sublimaze) Injection (Currently in Shortage)
 Meropenem for Injection, USP (Resolved)
 Sufentanil Citrate (Sufenta) Injection (Currently in Shortage)
 April 04, 2016
 Atropine Sulfate Injection (Currently in Shortage)
 Calcium Chloride Injection, USP (Currently in Shortage)
 Doxorubicin (Adriamycin) Injection (Currently in Shortage)
 Fentanyl Citrate (Sublimaze) Injection (Currently in Shortage)
 Imipenem and Cilastatin for Injection, USP (Currently in Shortage)
 Lidocaine Hydrochloride (Xylocaine) Injection (Currently in Shortage)
 Multi-Vitamin Infusion (Adult and Pediatric) (Currently in Shortage)
 Piperacillin and Tazobactam (Zosyn) Injection (Currently in Shortage)
 Sodium Bicarbonate Injection, USP (Currently in Shortage)
 Sodium Chloride 23.4% Injection (Currently in Shortage)
 Tobramycin Injection (Currently in Shortage)
 Vancomycin Hydrochloride for Injection, USP (Currently in Shortage)
FDA Drug Safety Communication:
FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin
and alogliptin
o http://www.fda.gov/Drugs/DrugSafety/ucm486096.htm
http://hmpemail.net/blaster/display.php?M=1816169&C=650bc7500c0804127d80187cd978ea9e&S=5899&L=
243&N=6097
FDA ACTIVITY
FDA Approves Biosimilar of Johnson and Johnson's Blockbuster Drug Remicade
The FDA has approved Inflectra (infliximab-dyyb, Celltrion Inc) for the treatment of multiple conditions,
including rheumatoid arthritis and inflammatory bowel disease.
FDA APPROVALS
This image cannot currently be displayed.
FDA Approves Venclexta for Patients With Chronic Lymphocytic Leukemia With 17p Deletion
The FDA has approved Venclexta (venetoclax, AbbVie Inc) for the treatment of chronic lymphocytic
leukemia in patients with a chromosomal abnormality called 17p deletion who have been previously treated
with at least one therapy.
FDA ACTIVITY
FDA Expands Use of Metformin to Include Patients With Renal Impairment
Metformin-containing medications can be used in certain patients with diabetes who have mild-to-moderate
kidney dysfunction.
HIPAA update
Ready or Not, It’s Time For Phase 2 HIPAA Audits
o http://www.jdsupra.com/legalnews/ready-or-not-it-s-time-for-phase-2-78715/
$1.55 million settlement underscores the importance of executing HIPAA business associate agreements
o http://www.hhs.gov/about/news/2016/03/16/155-million-settlement-underscores-importance-
executing-hipaa-business-associate-agreements.html
INSURANCE
New Medicare Payment Model Aims To Improve Primary Care
o http://www.consultant360.com/exclusives/new-medicare-payment-model-aims-improve-
primary-care
Pharmacy Drug Pricing
o https://www.medicaid.gov/Medicaid-CHIP-Program-Information/By-
Topics/Benefits/Prescription-Drugs/Pharmacy-Pricing.html
UPDATES
CARDIOLOGY USPSTF: Update to Aspirin Use Guidelines
o http://www.consultant360.com/exclusives/uspstf-update-aspirin-use-guidelines
Depression May Compound Diabetes Risk (from consultant360)
o New research investigates the association between depression and metabolic risk factors and the
likelihood of developing type 2 diabetes
o http://www.consultant360.com/topic/mental-health
New Prostate Technique May Help Men's Nighttime Urination
o https://www.nlm.nih.gov/medlineplus/news/fullstory_158125.html
IMMUNIZATIONS
http://www.immunize.org/express/issue1241.asp
CDC Vaccine Price List
o http://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/index.html
Zika fears escalate: Virus is scarier than previously thought, CDC says
o http://www.fiercehealthcare.com/story/zika-fears-escalate-virus-scarier-previous-thought-cdc-
says/2016-04-
14?utm_medium=nl&utm_source=internal&mkt_tok=eyJpIjoiTjJKak5XUTNObU5rTmpsaCIsIn
QiOiJtcmVub0l6K05HSFVJQXFYejY5aWh4ZzVhSldNQ0psbWRnaHNkXC94T3RKdlNzaUlu
MXVEaUZXSkppMXBCQkxtQ1lDVVR2dm5MREkrTnBTTWNEUThnOTIxR2NtT0pKeVN6
WVpuUzU3MUNpRUU9In0%3D
HOSPITAL
Joint Commission Resources
Patient safety
April 13, 2016
New Quick Safety focuses on implicit bias
o http://www.jointcommission.org/issues/article.aspx?Article=TjgKCr9s%2b3VowCidQsb%2b
E4yZbhTavTj%2fu0vzpKVtAHk%3d&j=2869101&e=randygc2011@yahoo.com&l=94_HT
ML&u=77598806&mid=1064717&jb=63
Upcoming events to help better understand Joint Commission requirements
Several events are coming up in mid-May to help health care organizations with accreditation. All of the
events will be held at the Westin Lombard, 70 Yorktown Shopping Center, in Lombard, Illinois:
 Hospital Accreditation Essentials: May 16-17. This interactive, solutions-based seminar is designed to
provide health care professionals with implementation tips for using Joint Commission hospital
requirements.
 Maximizing Hospital Tracer Activities: May 18. This single-day event is for hospital professionals seeking
an advanced workshop that includes the latest information on tracers, as well as recommendations and
strategies that can be implemented at their organizations.
 Home Care Accreditation Essentials: May 19-20. This is a strategy-based seminar aimed at helping
organizations with The Joint Commission’s home care requirements.
This image cannot currently be displayed.
NEWS
For Consumers: Seven Things Pregnant Women and Parents Need to Know About Arsenic in Rice and
Rice Cereal
o http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm493677.htm#1
Scientists Try to Stop Another Deadly Virus
o https://www.nlm.nih.gov/medlineplus/news/fullstory_158128.html
Doctors Often Overestimate Promise of Newly Approved Drugs
o Many misinterpret FDA 'breakthrough' designation, survey finds
o https://www.nlm.nih.gov/medlineplus/news/fullstory_158267.html
3 Findings on Colds You May Have Missed
o http://www.pharmacytimes.com/resource-centers/cough-cold/3-findings-on-colds-you-may-
have-
missed?utm_source=Informz&utm_medium=Pharmacy+Times&utm_campaign=PT_eNews
_Daily_Nasacort_4-5-16
Prediabetes May Damage Nerves More Than Thought
o Early pain and tingling in hands, feet may be 'canary in the coal mine,' researchers say
o https://www.nlm.nih.gov/medlineplus/news/fullstory_158274.html
**************************************
This content is copyright protected
However, if you would like to share the information in this article, you may use the headline, summary and
link below:
o Spanish regulators suspend Inmunotek's manufacturing license and order recall
o By Gareth MacDonald+, 13-Apr-2016
o Inmunotek has been ordered to recall vaccines made at a facility in Madrid after Spanish regulators
identified a number of GMP deficiencies.
o http://www.in-pharmatechnologist.com/Regulatory-Safety/Spanish-regulators-suspend-Inmunotek-
s-manufacturing-license-and-order-recall
**************************************
This content is copyright protected
o However, if you would like to share the information in this article, you may use the headline,
summary and link below:
o Pill attaches to GI tract lining for slow release
o By Melissa Fassbender, 11-Apr-2016
o Researchers have developed a new tablet that attaches to the lining of the GI tract and slowly
releases medication.
o http://www.in-pharmatechnologist.com/Drug-Delivery/Pill-attaches-to-GI-tract-lining-for-slow-
release
*****************************************
This content is copyright protected
o However, if you would like to share the information in this article, you may use the headline,
summary and link below:
o Oasmia looking to license Vitamin A-derived drug delivery tech
o By Dan Stanton+, 12-Apr-2016
o Oasmia Pharmaceutical has announced clinical results for its XR17 nanotechnology it says
validates the excipient as a potential drug delivery system.
o http://www.in-pharmatechnologist.com/Drug-Delivery/Oasmia-looking-to-license-Vitamin-A-
derived-drug-delivery-tech
